GRI Bio, Inc.

NasdaqCM:GRI

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

United States

Market Cap

USD 3.10 M

Share Price

USD 1.32

Avg Daily Volume

497,880

Change (1 day)

-5.71%

Change (1 year)

Change (YTD)

-85.62%

GRI Bio, Inc. Dividend Yield on June 20, 2025

GRI Bio, Inc. Dividend Yield is NA on June 20, 2025. Dividend yield measures the dividend per share relative to stock's price value; higher yield suggests higher dividend return.

GRI Bio, Inc. 52-week low Dividend Yield is NA on June 20, 2025, which is NA below the current Dividend Yield.
GRI Bio, Inc. 52-week low Dividend Yield is NA on June 20, 2025, which is NA below the current Dividend Yield.
GRI Bio, Inc. average Dividend Yield for the last 52 weeks is NA.

Daily

From:

To:

Zoom:

Key data

Date	Dividend Yield	Market Capitalization	Share Price	Share Price

NasdaqCM: GRI

GRI Bio, Inc.

CEO	Dr. W. Marc Hertz Ph.D.
IPO Date	Feb. 10, 2021
Location	United States
Headquarters	2223 Avenida de la Playa
Employees	3
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.